The behavior of biodegradable polylactide as a stent material has not yet been fully established in small vessels such as arteries with a diameter <3 mm. The aim of this study was to investigate the long-term effect of a copolymeric polylactide (PLA96) stent. Appropriately sized spiral PLA96 stents were implanted into the infrarenal aortas of 20 rabbits. Intraoperative systemic heparinization (150 IU/kg), perioperative subcutaneous enoxaheparin sodium (10 mg), ticlopidine (250 mg/day) for 1 month, and acetosalicylic acid (12.5 mg/day) were continuously administered. Animals were euthanized according to a fixed timetable for up to 34 months for histologic and scanning-electron-microscopic assessment. Endothelialization was complete within 1 month. In 2 of the 3 aortas sampled 3 months after implantation, a mild inflammatory reaction was visible, with no sign of granulomatous or foreign-body reaction in the vessel wall. Instead, in 1 sample examined at the same time point, neointimal chondroid metaplasia was detected. After 6 months, inflammatory reaction declined in the vessel wall. Hydrolyzation of the stent was histologically evident at 12 months, with mild foreign-body reaction detectable in 2 of 5 aortas sampled at this time point. The stent disintegrated without fragmentation by 24 months, as it was gradually replaced by fibrosis. The vessel lumen remained patent at all time points. We conclude that the PLA96 stent degraded with minimal tissue response within 24 months. PLA96 may thus be a promising stent core material for small vessels in the future, although further investigation is needed to establish its final biocompatibility.

Keywords:
Bioabsorbable stent, Biodegradable polylactide, Stent materials, Experimental study
1.
Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, Strandness DE Jr, Taylor LM: Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review. Circulation 1996;94:3026–3049.
2.
Tetteroo E, van der Graaf Y, Bosch JL, van Engelen AD, Hunink MG, Eikelboom BC, Mali WP: Randomized comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet 1998;351:1153–1159.
3.
Matsi PJ, Manninen HI, Suhonen MT, Pirinen AE, Soimakallio S: Chronic critical lower limb ischemia: Prospective trial of angioplasty with 1–36 months follow-up. Radiology 1993;188:381–387.
4.
Hanna GP, Fujise KF, Kjellgren O, Feld S, Fife C, Schroth G, Clanton T, Anderson V, Smalling RW: Infrapopliteal transcatheter interventions for limb salvage in diabetic patients: Importance of aggressive interventional approach and role of transcutaneous oximetry. J Am Coll Cardiol 1997;30:664–669.
5.
Schwarten DE: Clinical and anatomical considerations for nonoperative therapy in tibial disease and results of angioplasty. Circulation 1991;83(suppl I):I-86–I-90.
6.
Schomig A, Neumann FJ, Walter H, Schuhlen H, Hadamitzky M, Zitzmann-Roth EM, Dirschinger J, Hausleiter J, Blasini R, Schmitt C, Alt E, Kastrati A: Coronary stent placement in patients with acute myocardial infarction: Comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997;29:28–34.
7.
Hardhammar PA, van Beusekom HM, Emanuelsson HU, Hofma SH, Albertsson PA, Verdouw PD, Boersma E, Serruys PW, van der Giessen WJ: Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996;93:423–430.
8.
De Scheerder I, Wang K, Wilczek K, Meuleman D, Van Amsterdam R, Vogel G, Piessens J, Van de Werf F: Experimental study of thrombogenecity and foreign body reaction induced by heparin-coated coronary stents. Circulation 1997;95:1549–1553.
9.
Yamawaki T, Shimokawa H, Kozai T Miyata K, Higo T, Tanaka E, Egashira K, Shiraishi T, Tamai H, Igaki K, Takeshita A: Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 1998;32:780–786.
10.
Bilder G, Wentz T, Leadley R, Amin D, Byan L, O’Conner B, Needle S, Galczenski H, Bostwick J, Kasiewski C, Myers M, Spada A, Merkel L, Ly C, Persons P, Page K, Perrone M, Dunwiddie C: Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. Circulation 1999;99:3292–3299.
11.
Hehrlein C, Gollan C, Donges K, Metz J, Riessen R, Fehsenfeld P, von Hodenberg E, Kubler W: Low-dose radioactive endovascular stents prevent smooth muscle cell proliferation and neointimal hyperplasia in rabbits. Circulation 1995;92:1570–1575.
12.
Bruijninckx CMA, Levendag PC: Endovascular irradiation for the prevention of restenosis after percutaneous transluminal angioplasty. Eur J Vasc Endovasc Surg 1998;16:371–372.
13.
Herdeg C, Oberhoff M, Karsch KR: Antiproliferative stent coatings: Taxol and related compounds. Semin Interv Cardiol 1998;3:197–199.
14.
Klugherz BD, Lianos G, Lieuallen W, Kopia G, Papandreou G, Natrayan P, Levengood T, Sasseen B, Adelman S, Falotico R, Wilensky RL: Stent-based delivery of sirolismus for the prevention of restenosis. J Am Coll Cardiol 2000;35(suppl A):58A.
15.
Bos R: Poly(L-lactide) osteosynthesis development of bioabsorbable bone plates and screws; thesis. University of Groningen, 1989.
16.
Mero M, Vainionpää S, Vasenius J, Vihtonen K, Rokkanen P: Medetomidine-ketamine-diazepam anesthesia in the rabbit. Acta Vet Scand 1989;S85:135–137.
17.
Barth K, Virmani R, Froelich J, Takeda T, Lossef SV, Newsome J, Jones R, Lindisch D: Paired comparison of vascular wall reactions to Palmaz stents, Strecker tantalum stents, and wall stents in canine iliac and femoral arteries. Circulation 1996;94:2161–2169.
18.
Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R: Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44–52.
19.
Kornowski R, Hong MK, Virmani R, Jones R, Vodovotz Y, Leon MB: Granulomatous ‘foreign body reactions’ contribute to exaggerated in-stent restenosis. Coron Artery Dis 1999;10:9–14.
20.
Coltran RS, Kumar V, Robbins S: Cellular growth and differentiation; in Coltran RS, Kumar V, Robbins S (eds): Pathologic Basis of Disease, ed 5. Philadelphia, Saunders, 1994, p 48.
21.
Dvorak P, Bucek J, Cerny E, Zampachova V: Heterotopic chondro-osteoplastic metaplasia of the subclavian vein wall after long-term catheterization. Case report. Cesk Patol 1999;35:27–29.
22.
Bertrand OF, Sipehia R, Mongrain R, Rodes J, Tardif JC, Bilodeau L, Cote G, Bourassa MG: Biocompatibility aspects of new stent technology. J Am Coll Cardiol 1998;32:562–571.
23.
Isotalo T, Tammela TL, Talja M, Välimaa T, Törmälä P: A bioabsorbable self-expandable, self-reinforced poly-L-lactide acid urethral stent for recurrent urethral strictures: A preliminary report. J Urol 1998;160:2033–2336.
24.
Korpela A, Aarnio P, Sariola H, Törmälä P, Harjula A: Bioabsorbable self-reinforced poly-L-lactide, metallic, and silicone stents in the management of experimental tracheal stenosis. Chest 1999;115:490–495.
25.
Gao R, Shi R, Qiao S, Song L, Li Y: A novel polymeric local heparin delivery stent: Initial experimental study. J Am Coll Cardiol 1996;27:85A.
26.
Ye YW, Landau C, Willard JE, Rajasubramanian G, Moskowitz A, Aziz S, Meidell RS, Eberhart RC: Bioresorbable microporous stents deliver recombinant adenovirus gene transfer vectors to the arterial wall. Ann Biomed Eng 1998;26:398–408.
27.
Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H: Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000;102:399–404.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.